Prostatic specific antigen, total & free

Alphabetical Test listing

Prostatic specific antigen, total & free-4765

  
Prostatic specific antigen, total & free
  
4765
  
LAB4765
  
PST
  
PSA, total & free
Prostatic specific antigen
  

The test method changed on 1/3/2023. If this test has been used for serial monitoring, rebaselining is recommended. Rebaselining consists of 2 measurements, collected 3-6 weeks apart.
The Roche Elecsys CEA assay is an electrochemiluminescence immunoassay "ECLIA" performed on the Roche Cobas "e" immunoassy analyzers.
Values obtained with different assay methods may be different and cannot be used interchangeably.

  
Serum
  
  
2.0 mL
  
0.4 mL
  
  • It is recommended to obtain specimens for PSA testing prior to procedures involving manipulation of the prostate.
  • Immediatley following collection, mix sample by inverting 5 times
  
  1. Allow sample to clot for a minimum of 30 minutes
  2. Spin within two (2) hours of sample collection
  

Gold serum separator (SST) tube

  
Serum
Lithium heparin (Li hep) plasma
  

Immediatley following collection, mix sample by inverting 5 times

  

Red:

  1. Allow sample to clot
  2. Spin
  3. Transfer serum to a False bottom plasma/serum transport vial/tube (AHL), labelled as serum, within two (2) hours of sample collection

Lt green:

  1. Spin within two (2) hours of sample collection
  
  

Refrigerated (preferred) - 5 days

Frozen - 3 months

Ambient - 8 hours

  
  • Improper labels (unlabeled or mislabeled)
  • Hemolysis (some procedures)
  • Improper anticoagulant or ratio
  • Delay in transport
  • Improper storage temperature affecting results
  • Improper container
  • Leaking container resulting in compromised specimen
  • Quantity not sufficient (QNS)
  
AHL - Chemistry: C
  
Daily
  
2 - 3 days
  

Electrochemiluminescence immunoassay (ECLIA)

  

When the total PSA is <4.0 or >10.0, the % Free PSA will not be calculated.  The % Free PSA will be reported as "Not Specified"

In patients with total PSA concentrations between 4.0 and 10.0 ng/mL, the Prostate Health Index (PHI) may aid in distinguishing prostate cancer from benign prostate conditions.

Values obtained with different assay methods may be different and cannot be used interchangeably.

 

  
84154
84153
  
Yes
  
  
11/30/2001
  
05/23/2024
  
05/10/2024